Posted on October 7th, 2020 by Xuanyan Xu in Pharma R&D
DNA-encoded
libraries (DELs) have been gaining a lot of traction in hit finding and drug
discovery in recent years. Regarded by some as a truly revolutionary advance in
chemistry, a DEL is a mixture of millions of small molecules in which each
molecule is conjugated to a DNA-oligomer that encodes its chemical structure.
The mixture can be stored in a simple test tube.
DEL screening is now being widely used by pharmaceutical companies to find novel chemical matter that modulates protein targets of interest. As Chemical & Engineering News has reported, there have been a quickly growing number of industry deals in this space. Vertex Pharmaceuticals has paired up with X-Chem in order to utilize their DELs for drug discovery. Amgen acquired Nuevolution to use the biotech’s DELs in search of drug candidates. And Hitgen has partnered with heavy hitters like Johnson & Johnson, Merck, and Pfizer.
Dr. Andreas Brunschweiger, Faculty of Chemistry and Chemical Biology at TU Dortmund University, has been engaged in interesting research involving DNA-encoded chemical libraries and addressing some of the challenges in using them as a small molecule screening technology. In an upcoming webinar, he will be presenting some insights from his research.
Scheduled for
October 14, the webinar will feature Dr. Alex Satz, senior director of DEL
strategy and operations at WuXi AppTec, giving an informative overview of DELs.
This will be followed by a presentation from Dr. Brunschweiger on research
showing how a cheminformatics workflow can inform DEL design, and how the
screening of a proof of concept DNA-encoded library led to compound
identification.
To learn more about this research and DELs, register here to attend the webinar.
Please enable JavaScript to view the comments powered by Disqus.
R&D Solutions for Pharma & Life Sciences
We’re happy to discuss your needs and show you how Elsevier’s Solution can help.
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()
{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
;if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘533182150132648’);
fbq(‘track’, “PageView”);
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()
{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
;if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘1737613393127776’,
{ em: ‘insert_email_variable,’ }
);
fbq(‘track’, ‘PageView’);
